Management of Hepatic Granulomatous Tuberculosis After BCG Therapy for Bladder Cancer
| Autor: | Solmaz Ohadian Moghadam, Mohsen Ayati, Hossein Ghorani, Afshin Mortazavi, Mohammad Reza Nowroozi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Tuberculosis Urology Bcg therapy lcsh:RC870-923 Gastroenterology 03 medical and health sciences BCG therapy Internal medicine medicine Hepatic granulomatous tuberculosis Bladder cancer business.industry Treatment method lcsh:Diseases of the genitourinary system. Urology medicine.disease Surgery 030104 developmental biology Oncology Superficial bladder cancer Granulomatous Hepatitis Prednisolone Complication business medicine.drug |
| Zdroj: | Urology Case Reports Urology Case Reports, Vol 13, Iss C, Pp 158-159 (2017) |
| ISSN: | 2214-4420 |
| Popis: | BCG therapy is used as a treatment in bladder cancer. Intravesical administration of Bacillus Calmette-Guérin is used as a treatment method in superficial bladder cancer. While it is commonly effective, some serious side effects may occur. We hereby report a 65-year-old man who developed granulomatous hepatitis as a complication following BCG therapy. He was treated successfully with antitubercular therapy and prednisolone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|